Immunotherapy of acute myeloid leukaemia.
Open Access
- 1 January 1978
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 37 (1), 1-14
- https://doi.org/10.1038/bjc.1978.1
Abstract
Seventy-one patients suffering from acute myeloid leukaemia (AML) who were already in complete remission and had already received one further course of cytotoxic drugs as consolidation therapy were randomised to receive maintenance chemotherapy alone or the same maintenance chemotherapy plus immunotherapy with BCG and irradiated allogeneic blast cells. The duration of first remission was slightly, but not significantly, longer in those patients who received immunotherapy. This was true also for the duration of survival after relapse. Comparison with other series suggested that the effect of such immunotherapy on duration of survival after relapse is probably real, but did not clearly indicate whether or not any real difference in the first remission duration existed.Keywords
This publication has 7 references indexed in Scilit:
- Immunotherapy for acute myelogenous leukaemia: a controlled clinical study 2 1/2 years after entry of the last patientBritish Journal of Cancer, 1977
- The Immunotherapy of Acute Myelogenous Leukaemia using Intravenous BCGBritish Journal of Haematology, 1977
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and designBritish Journal of Cancer, 1976
- BCG in the treatment of acute lymphocytic leukemia.1975
- Active Immunotherapy Used Alone for Maintenance of Patients with Acute Myeloid LeukaemiaBMJ, 1973
- Immunotherapy for Acute Myelogenous LeukaemiaBritish Journal of Cancer, 1973
- ACTIVE IMMUNOTHERAPY FOR ACUTE LYMPHOBLASTIC LEUKÆMIAThe Lancet, 1969